BiotechTube
Kinnov Therapeutics

Kinnov Therapeutics

Lyon, France· Est.
kinnov-therapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20M

Overview

Kinnov Therapeutics is a private, Phase 3-stage biotech company focused on developing disruptive pharmacological treatments for addiction, including alcohol, tobacco, cocaine, and opioids. Its core innovation is KT-110, a patented combination of two repurposed drugs (prazosin and cyproheptadine) in a novel galenic formulation designed for once-daily dosing. Backed by over 20 years of research, the company has secured support from European funds and key partners, with its Phase 2 results published in the prestigious journal 'Addiction'.

AddictionPsychiatryCentral Nervous System

Technology Platform

A disruptive pharmacological strategy based on the rational combination and repurposing of existing drugs (prazosin and cyproheptadine) to treat addiction, supported by a patented novel galenic formulation enabling once-daily dosing.

Funding History

3
Total raised:$20M
Series A$15M
Seed$2.5M
Seed$2.5M

Opportunities

The primary opportunity is addressing the vast, underserved global market of over 35 million people with addiction disorders, starting with severe Alcohol Use Disorder.
Success with KT-110 could lead to expansion into other substance use disorders (tobacco, cocaine, opioids), significantly multiplying the addressable market.
The novel once-daily formulation provides a key competitive advantage in patient adherence.

Risk Factors

Key risks include the inherent uncertainty of Phase 3 clinical trial outcomes, regulatory challenges across multiple regions (FDA, EMA), and the need to secure substantial financing to complete late-stage development.
As a small biotech, future commercialization would require a strategic partner or significant capital to build a sales force, posing execution and dilution risks.

Competitive Landscape

Kinnov competes in the Alcohol Use Disorder pharmacotherapy market against established drugs like naltrexone, acamprosate, and disulfiram, as well as newer approaches like psychedelics. Its main differentiation lies in KT-110's first-in-class dual-mechanism (prazosin + cyproheptadine), proven efficacy in a severe patient population from Phase 2, and a patented, convenient once-daily formulation designed to improve real-world adherence.

More companies in Small Molecule Drugs →More companies in France →